TARDBP and Primary lateral sclerosis: Igaz et al. (2011) originally used the Camk2a promotor to drive disruption of the NLS sequence of TDP‐43 predominantly in upper MNs, sparing lower spinal MNs and thus resembling a mouse model of peripheral lateral sclerosis (PLS) (Igaz et al. 2011).